Visual Perceptual Remediation for Schizophrenia
(VRiS Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new visual training program for people with schizophrenia, aiming to improve how they see and organize visual information. Participants are divided into groups to try various exercise combinations, including one that combines two types of visual training (UltimEyes and Contour Integration Training) and another that focuses on general cognitive skills. The researchers aim to determine which method most effectively improves visual and community functioning. This trial suits those diagnosed with schizophrenia who haven't recently changed their medication and don't have an eye disease. As an unphased trial, participants can contribute to innovative research that could enhance treatment options for schizophrenia.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, you must be clinically stable, meaning no changes in your antipsychotic medication in the last month or two, depending on the type.
What prior data suggests that this visual remediation intervention is safe for people with schizophrenia?
Research has shown that the safety of visual perceptual treatments like UltimEyes and Contour Integration Training isn't well-documented in existing studies. However, these treatments use non-invasive methods to enhance the brain's processing of visual information, making physical side effects less likely.
For UltimEyes, no specific reports of negative effects have emerged from its use in improving the brain's handling of visual inputs. Contour Integration Training aids the brain in organizing visual information more effectively. Although detailed safety data remains limited, this method is generally considered low-risk due to its non-invasive nature.
Since these treatments work by training the brain through visual exercises, they are less likely to cause harm. It is important to note that research on these treatments is ongoing, and participants will be closely monitored for any unexpected reactions.12345Why are researchers excited about this trial?
Researchers are excited about these treatments for schizophrenia because they offer new ways to enhance visual processing, which is often impaired in this condition. Contour Integration Training focuses on improving how patients perceive visual patterns, potentially enhancing their overall cognitive function. UltimEyes is a digital tool designed to boost contrast sensitivity, which can help patients better interpret visual information. The combination of UltimEyes and Contour Integration Training aims to maximize these benefits, providing a comprehensive approach to visual and cognitive remediation not typically addressed by standard antipsychotic medications. These innovative strategies could complement existing treatments by targeting the sensory and perceptual difficulties that are not usually the main focus of current therapies.
What evidence suggests that this trial's treatments could be effective for schizophrenia?
Studies have shown that specific training methods can improve visual perception problems in people with schizophrenia. In this trial, participants may receive UltimEyes, a program that enhances contrast sensitivity and has demonstrated significant positive effects on visual processing. Another group will receive Contour Integration Training, which research indicates can quickly improve shape and pattern recognition. Additionally, some participants will receive a combination of UltimEyes and Contour Integration Training to enhance both contrast sensitivity and the ability to organize visual information, potentially leading to better overall visual functions. Although researchers are still studying these methods, early results suggest they could greatly enhance visual thinking and everyday functioning for people with schizophrenia.678910
Who Is on the Research Team?
Steven M Silverstein, Ph.D.
Principal Investigator
University of Rochester
Are You a Good Fit for This Trial?
This trial is for individuals aged 18-60 with a diagnosis of schizophrenia, who speak English and can complete basic cognitive tests. They should be clinically stable with no recent medication changes and have at least a 6th-grade reading level. People with eye diseases, recent substance abuse, intellectual disabilities, or significant brain trauma are not eligible.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Phase 1 Treatment
Participants undergo interventions targeting contrast sensitivity and perceptual organization, including ULTIMEYES and Contour Integration Training, with assessments after every 10 sessions
Phase 2 Treatment
Randomized controlled trial of the optimal treatment identified in Phase 1, with a focus on visual target engagement and associated improvements
Follow-up
Participants are monitored for safety and effectiveness after treatment, with outcome measures including visual functioning, cognition, and community functioning
What Are the Treatments Tested in This Trial?
Interventions
- Contour Integration Training
- MyBrainSolutions
- UltimEyes
- UltimEyes + Contour Integration Training
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Rochester
Lead Sponsor
National Institute of Mental Health (NIMH)
Collaborator
Weill Medical College of Cornell University
Collaborator
New York University
Collaborator